139 related articles for article (PubMed ID: 23283650)
1. Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.
Huang J; Wang T; Huang Y
Med Oncol; 2013 Mar; 30(1):436. PubMed ID: 23283650
[No Abstract] [Full Text] [Related]
2. Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma.
Edeline J; Laguerre B; Rolland Y; Patard JJ
Ann Oncol; 2010 Jan; 21(1):186-7. PubMed ID: 19875754
[No Abstract] [Full Text] [Related]
3. Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma.
Quintyne KI; Neenan T; Casserly L; Gupta R
BMJ Case Rep; 2014 May; 2014():. PubMed ID: 24872478
[TBL] [Abstract][Full Text] [Related]
4. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
De Vincenzo F; Zucali PA; Ceresoli GL; Colombo P; Simonelli M; Lorenzi E; Perrino M; Gianoncelli L; De Sanctis R; Graziotti P; Santoro A
J Clin Oncol; 2011 Jun; 29(18):e529-31. PubMed ID: 21483010
[No Abstract] [Full Text] [Related]
5. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
6. Acute cardiac failure after sunitinib.
Machiels JP; Bletard N; Pirenne P; Jacquet L; Bonbled F; Duck L
Ann Oncol; 2008 Mar; 19(3):597-9. PubMed ID: 18272908
[No Abstract] [Full Text] [Related]
7. Pyoderma gangrenosum with the use of sunitinib.
Nadauld LD; Miller MB; Srinivas S
J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
[No Abstract] [Full Text] [Related]
8. Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
Ruggeri EM; Cecere FL; Moscetti L; Doni L; Padalino D; Di Costanzo F
Ann Oncol; 2010 Sep; 21(9):1926-1927. PubMed ID: 20729535
[No Abstract] [Full Text] [Related]
9. Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib.
Niwa N; Nishiyama T; Ozu C; Yagi Y; Saito S
Acta Oncol; 2015 Apr; 54(4):561-2. PubMed ID: 25291078
[No Abstract] [Full Text] [Related]
10. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
Méjean A; Ravaud A; Thezenas S; Colas S; Beauval JB; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Beisland C; Aitchison M; Oudard S; Patard JJ; Theodore C; Chevreau C; Laguerre B; Hubert J; Gross-Goupil M; Bernhard JC; Albiges L; Timsit MO; Lebret T; Escudier B
N Engl J Med; 2018 Aug; 379(5):417-427. PubMed ID: 29860937
[TBL] [Abstract][Full Text] [Related]
11. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
12. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
[TBL] [Abstract][Full Text] [Related]
13. Three cases of severe ulcerative esophagitis induced by SUTENT®.
Jeanniard-Malet O; Gravis G; Caillol F; Pesenti C; Bories E; Giovannini M
J Gastrointest Cancer; 2012 Mar; 43(1):128-30. PubMed ID: 20640604
[TBL] [Abstract][Full Text] [Related]
14. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
15. Management of antiangiogenic therapy-induced hypertension.
de Jesus-Gonzalez N; Robinson E; Moslehi J; Humphreys BD
Hypertension; 2012 Sep; 60(3):607-15. PubMed ID: 22851729
[No Abstract] [Full Text] [Related]
16. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ
J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770
[TBL] [Abstract][Full Text] [Related]
17. Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
van den Meiracker AH; Danser AH; Sleijfer S; Kappers MH
J Natl Cancer Inst; 2011 Oct; 103(20):1557; author reply 1558. PubMed ID: 21862728
[No Abstract] [Full Text] [Related]
18. Hypertension as a predictive factor of Sunitinib activity.
Rixe O; Billemont B; Izzedine H
Ann Oncol; 2007 Jun; 18(6):1117. PubMed ID: 17586751
[No Abstract] [Full Text] [Related]
19. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
Kalantari HR
Br J Cancer; 2009 Oct; 101(7):1222-3; author reply 1224. PubMed ID: 19755985
[No Abstract] [Full Text] [Related]
20. Sunitinib-aggravated hypertension.
Rivera F; Benounna M; Sánchez de la Nieta MD
J Hypertens; 2009 Jul; 27(7):1502-3. PubMed ID: 19542988
[No Abstract] [Full Text] [Related]
[Next] [New Search]
